Humana Coverage Policy For Gilenya Promotes Second-Line Use
Executive Summary
Humana’s medical coverage policy for Novartis’ new multiple sclerosis drug Gilenya (fingolimod) requires prior authorization documenting the patient has already tried and failed treatment with other drugs.